A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
A new poll shows the centre-right Tisza party maintaining an eight-point advantage over the ruling Fidesz, setting the stage for Hungary's most consequential vote in over a decade, with major implications for Europe's political landscape.
Amid a market environment of stable rates and mixed sentiment, we highlight three companies—spanning biotech, gaming, and tech hardware—whose current share prices appear significantly below their estimated intrinsic value based on cash flow projections.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
Ethereum's price has plunged 27% in five days, bringing it perilously close to the $2,000 threshold. While fear-driven selling dominates, on-chain metrics suggest the sell-off may be nearing exhaustion, potentially setting the stage for a long-term recovery.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
Despite posting robust year-over-year growth, Brown & Brown's Q4 revenue miss triggered a sharp sell-off. The earnings call revealed deeper pressures, from integration challenges and talent poaching to market normalization, setting the stage for a pivotal 2024.
Recent share price weakness at French construction giant Compagnie de Saint-Gobain has investors questioning its valuation. While a key model suggests the stock is fairly priced, its low P/E ratio compared to peers hints at potential undervaluation, setting the stage for a nuanced debate on the stock's true worth.
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.
As gold and silver surged to record highs last month, Bitcoin's puzzling stagnation below $90,000 had traders searching for answers. A closer look at exchange order books reveals a deliberate play by large players to suppress price—a tactic that ultimately set the stage for last week's sharp decline.
As Thailand heads to the polls, three major parties offer starkly different visions for the nation's path forward, from populist subsidies to structural reforms, setting the stage for a pivotal political contest.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
Amidst a cautiously optimistic Asian market, companies where executives and directors hold significant stakes are drawing investor attention. We examine three high-conviction plays in semiconductors, 3D printing, and biotech where insider ownership aligns with explosive growth forecasts.
A unique shareholder structure at German IT firm All for One Group SE sees individual investors wielding influence equal to its largest corporate shareholder, setting the stage for potential shifts in corporate governance and strategy.
IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.
Glaukos shares have rebounded nearly 8% in a month, yet remain down sharply over the past year. A deep dive into the numbers reveals a stark contrast: a discounted cash flow model suggests significant upside, while price-to-sales metrics paint a picture of a richly valued stock. Investors are left weighing the promise of future glaucoma innovation against current market multiples.
Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.
